Asmaa Beltagy: Efficacy and Safety of Eltrombopag in SLE-Associated Immune Thrombocytopenia
Asmaa Beltagy, Lecturer and Attending of Internal Medicine and Rheumatology at Alexandria University Faculty of Medicine, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Lupus, adding:
“Happy to share that our paper has been accepted in Lupus!
‘Eltrombopag in the treatment of immune thrombocytopenia secondary to SLE: A double-edged sword’
We looked at both the efficacy and the safety of eltrombopag in SLE-associated immune thrombocytopenia, with a particular focus on thrombotic risk, a question that matters at the bedside when we reach for this drug in patients who may already be prothrombotic.
Huge thanks to my co-authors for their work and collaboration on this project.
Grateful to keep contributing to lupus research.”
Title: Eltrombopag in the treatment of immune thrombocytopenia secondary to SLE: A double-edged sword
Authors: Asmaa Beltagy, Abeer Abdelati, Fatma Fayed, Nouran Eshak, Ashraf Elghandour, Mohamed H. Elbahoty

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice